Mark Stejbach, Merck
S
Mark Stejbach
VP, Managed Care Marketing, Merck
DOUBLE DUTY: Is helping build Merck's new healthcare model
OF NOTE: First non-finance person to run Merck's investor relations
On payers:
For many years, the success of the industry was at least in part driven by the inefficiency of the economic model of healthcare. In the short term, there's always more to be eked out from the current model—and I think some companies are going to run with that as hard and as long as they can. But in the long term, companies have to understand that the market is going to be increasingly influenced by the people who pay the bills—payers and consumers. In that way, pharma will start to become more like most other industries.
Mark Stejbach
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
